Buy Rating Affirmed for Viking Therapeutics Amidst Strong Clinical Progress and Strategic Moves

TipRanks02:10 ET

Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday

Health care stocks were leaning lower pre-bell Thursday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.1%. AstraZeneca (AZN) shares were u

MT NewswiresApr 25 09:01 ET

Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target

BenzingaApr 25 07:19 ET

Viking Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 42.56% HC Wainwright & Co. → $90 Reiterates Buy → Buy 03/27/2024 118.6% Oppenheimer $116 → $138

BenzingaApr 25 07:18 ET

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)

TipRanksApr 25 06:30 ET

Express News | Viking Therapeutics Shares Down 1.9% Premarket After Q1 Results

ReutersApr 25 06:16 ET